Key result
The 2022 PHA Scientific Sessions highlight recent progress in PH diagnosis, risk stratification, and treatment.
Why the study?
To summarize key messages and scientific and management updates across pulmonary hypertension topics presented at the 2022 Pulmonary Hypertension Association Scientific Sessions.
Summarizes key messages and updates in the diagnosis, risk stratification, and treatment of pulmonary hypertension from the 2022 Pulmonary Hypertension Association Scientific Sessions.
The considerable progress made in recent years in the diagnosis, risk stratification, and treatment of pulmonary hypertension was highlighted during the most recent edition of the Pulmonary Hypertension Association Scientific Sessions, which was held in Atlanta, Georgia from June 9 to 11, 2022, with the theme: Vision for the PHuture: The Evolving Science and Management of PH. Content presented over the 3-day conference focused on scientific and management updates since the last sessions were held in 2018 and included didactic talks, debates, and roundtable discussions across a broad spectrum of topics related to pulmonary hypertension. This article aims to summarize the key messages from each of the session talks.
No takes yet. Share an insight, caveat, or question.
Alamri et al. (2022) conducted a review in Pulmonary hypertension. The 2022 Pulmonary Hypertension Association Scientific Sessions highlighted recent progress in the diagnosis, risk stratification, and treatment of pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: